News
December 7, 2021
Obsidian Therapeutics Appoints Lee Giguere, J.D., as Chief Legal Officer and Corporate Secretary
CAMBRIDGE, Mass., Dec. 7, 2021 – Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Lee Giguere as Chief Legal Officer and Secretary. Lee will manage the legal function and serve as a key member of Obsidian’s executive leadership team, playing a critical role in the company’s strategic decision-making. He will provide operational leadership across a wide array of legal, governance and compliance matters.
“Lee’s broad experience in legal and corporate governance will be critical to Obsidian’s rapid growth as a company pioneering engineered TIL therapy,” commented Paul Wotton, Obsidian’s Chief Executive Officer. “The leadership he brings will strengthen our management team and together with his significant expertise in all legal and compliance matters, further positions Obsidian for success as we take our first cytoTIL15 program (OBX-115) into the clinic in 2022.”
Lee has wide-ranging experience and expertise in legal, healthcare compliance and corporate governance for public life science companies. He most recently served as general counsel and secretary at the biotechnology company Chiasma, Inc., responsible for all legal, compliance and human resource matters. Before joining Chiasma, he spent several years with Karyopharm Therapeutics Inc., an innovation-driven pharmaceutical company, as deputy general counsel, assistant secretary and Boston Scientific Corporation as senior securities and governance counsel. Lee began his legal career as an associate in the business law practice with Goodwin Procter. Lee earned his J.D. from Northeastern University School of Law and his B.S. from Northeastern University.
About OBX-115
OBX-115 is Obsidian’s lead cytoTIL15 program, currently in preclinical development for the treatment of patients with metastatic melanoma and other solid tumors. OBX-115 is a novel engineered tumor infiltrating lymphocyte therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs. The Company expects to submit an IND for OBX-115 in mid-2022.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Media Contact:
Maggie Beller
Russo Partners, LLC
Maggie.beller@russopartnersllc.com
646-942-5631